Osteoporosis and Dementia: Establishing a Link

Lary, Christine W.; Rosen, Clifford J; Kiel, Douglas P.

doi:10.1002/jbmr.4431

Cited by 12 publications

(9 citation statements)

References 42 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 45 These conditions have all been shown to be associated with increased risk of cognitive deficits or decline. 46 , 47 , 48 Taken together these studies suggest AAC, may be an early marker of systemic atherosclerotic vascular disease burden and capture non-traditional cardiovascular disease risk factors compared to CAC. Hence AAC is likely to add new information on the risk of late-life dementia compared to CAC alone.…”

Section: Discussionmentioning

confidence: 86%

Abdominal aortic calcification on lateral spine images captured during bone density testing and late-life dementia risk in older women: A prospective cohort study

Porter

Sim

Prince

et al. 2022

The Lancet Regional Health - Western Pacific

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Abdominal aortic calcification on lateral spine images captured during bone density testing and late-life dementia risk in older women: A prospective cohort study

Porter

Sim

Prince

et al. 2022

The Lancet Regional Health - Western Pacific

Self Cite

View full text Add to dashboard Cite

“…Osteoporotic fracture rates and bisphosphonate persistence outcomes were compared between the GR risedronate and the IR risedronate/alendronate cohorts both overall and in the following three subgroups of women considered to have high risk of fracture at the index date: (a) women aged ≥ 65 years [ 16 ], (b) women aged ≥ 70 years [ 16 ], and (c) women with other fracture risk factors (i.e., heart failure, chronic pulmonary disease, dementia, depression, diabetes, Parkinson’s disease comorbidities; prior osteoporotic fracture; or treatment with proton-pump inhibitors, sedatives, systemic corticosteroids, or loop diuretics [ 3 , 17 , 18 ], identified based on ≥ 1 relevant diagnosis code or treatment dispensing in the baseline period).…”

Section: Methodsmentioning

confidence: 99%

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA

Eisman

Cortet²,

Boolell³

et al. 2023

Osteoporos Int

View full text Add to dashboard Cite

The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate. A large proportion of women discontinued all oral bisphosphonate therapies within 1 year of treatment start. Purpose Using a US claims database (2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019), we compared risk of fractures between women with osteoporosis initiated on gastro-resistant (GR) risedronate and those initiated on (a) immediate release (IR) risedronate or (b) immediate release alendronate. Methods Women aged ≥ 60 years with osteoporosis who had ≥ 2 oral bisphosphonate prescription fills were followed for ≥ 1 year after the first observed bisphosphonates dispensing (index date). Fracture risk was compared between the GR risedronate and IR risedronate/alendronate cohorts using adjusted incidence rate ratios (aIRRs), both overall and in subgroups with high fracture risk due to older age or comorbidity/medications. Site-specific fractures were identified based on diagnosis codes recorded on medical claims using a claims-based algorithm. Persistence on bisphosphonate therapy was evaluated for all groups. Results aIRRs generally indicated lower fracture risk for GR risedronate than IR risedronate and alendronate. When comparing GR risedronate to IR risedronate, statistically significant aIRRs (p < 0.05) were observed for pelvic fractures in the full cohorts (aIRRs = 0.37), for any fracture and pelvic fractures among women aged ≥ 65 years (aIRRs = 0.63 and 0.41), for any fracture and pelvic fractures among women aged ≥ 70 years (aIRRs = 0.69 and 0.24), and for pelvic fracture among high-risk women due to comorbidity/medications (aIRR = 0.34). When comparing GR risedronate to alendronate, statistically significant aIRRs were observed for pelvic fractures in the full cohorts (aIRR = 0.54), for any fracture and wrist/arm fractures among women aged ≥ 65 years (aIRRs = 0.73 and 0.63), and for any fracture, pelvic, and wrist/arm fractures among women aged ≥ 70 years (aIRRs = 0.72, 0.36, and 0.58). In all cohorts, ~ 40% completely discontinued oral bisphosphonates within 1 year. Conclusions Discontinuation rates of oral bisphosphonate therapy were high. However, women initiated on GR risedronate had a significantly lower risk of fracture for several skeletal sites than women initiated on IR risedronate/alendronate, particularly those aged ≥ 70 years.

show abstract

“…Drugs targeting SLC13A5/INDY are now available and are reported to work in vitro [ 101 ] and in vivo [ 104 ]. Furthermore, bone is the main site of citrate storage in mammals, and bone demineralization is likely to release citrate in individuals with osteoporosis, which has recently been linked with dementia in humans [ 105 , 106 ].…”

Section: Citrate Transport and Its Role In Ageing And Diseasementioning

confidence: 99%

Metabolic Alterations in Cellular Senescence: The Role of Citrate in Ageing and Age-Related Disease

Mycielska

James

Parkinson

2022

IJMS

View full text Add to dashboard Cite

Recent mouse model experiments support an instrumental role for senescent cells in age-related diseases and senescent cells may be causal to certain age-related pathologies. A strongly supported hypothesis is that extranuclear chromatin is recognized by the cyclic GMP–AMP synthase-stimulator of interferon genes pathway, which in turn leads to the induction of several inflammatory cytokines as part of the senescence-associated secretory phenotype. This sterile inflammation increases with chronological age and age-associated disease. More recently, several intracellular and extracellular metabolic changes have been described in senescent cells but it is not clear whether any of them have functional significance. In this review, we highlight the potential effect of dietary and age-related metabolites in the modulation of the senescent phenotype in addition to discussing how experimental conditions may influence senescent cell metabolism, especially that of energy regulation. Finally, as extracellular citrate accumulates following certain types of senescence, we focus on the recently reported role of extracellular citrate in aging and age-related pathologies. We propose that citrate may be an active component of the senescence-associated secretory phenotype and via its intake through the diet may even contribute to the cause of age-related disease.

show abstract

Osteoporosis and Dementia: Establishing a Link

Cited by 12 publications

References 42 publications

Abdominal aortic calcification on lateral spine images captured during bone density testing and late-life dementia risk in older women: A prospective cohort study

Abdominal aortic calcification on lateral spine images captured during bone density testing and late-life dementia risk in older women: A prospective cohort study

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA

Metabolic Alterations in Cellular Senescence: The Role of Citrate in Ageing and Age-Related Disease

Contact Info

Product

Resources

About